Anbio Biotechnology Class... (NNNN)
7.40
-0.12 (-1.60%)
At close: Mar 25, 2025, 3:59 PM
7.48
1.12%
Pre-market: Mar 26, 2025, 06:32 AM EDT
Company Description
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.
It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products.
It serves over-the-counter, point-of-care testing, and laboratory markets.
The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Anbio Biotechnology Class A Ordinary Shares
| Country | DE |
| IPO Date | Feb 19, 2025 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Michael Lau M.B.A., Ph.D. |
Contact Details
Address: Wilhelm Gutbrod Str 21B Frankfurt am Main, DE | |
| Website | https://www.anbio.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | KYG0367B1059 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Michael Lau M.B.A., Ph.D. | Chief Executive Officer |
| Suki Song CPA | Chief Financial Officer |
| Chris Tian | Chief Business Officer |